BioSpace News Archive

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced today the appointment of Mr. Alek Krstajic and Mr. Eugene Siklos to the Board of Directors, effective immediately. Mr. Krstajic is the former Chief E

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has applied its novel DEP® drug delivery technology to create a long‑acting, water soluble version of remdesivir.

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Quellor™

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM),4 announced today its next-generation FreeStyle® Libre 2 integrated continuous glucose monitoring (iCGM) system is now available to Medicare patients.

Combinati Absolute Q® and Combinati |Q| SARS-CoV-2 Triplex Assay Provide Researchers with More Accurate, Precise and Sensitive Virus Detection

Global leader in fighting blood cancer, The Leukemia & Lymphoma Society, remains laser-focused on its mission amidst pandemic

ResMed (NYSE: RMD, ASX: RMD) announced today the launch of its AirTouch N20 nasal mask, the company’s first CPAP nasal mask with a memory foam cushion and softest nasal mask ever.

Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today provided an update on its ongoing APVO436 Phase 1/1b clinical trial

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, issued the following statement concerning the progress of the Company’s operations.

Clear Creek Bio, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for brequinar for the treatment of COVID-19 and has dosed the first patient in a Phase 1 clinical study.